BUSINESS

• Takeda in Talks with Shire after 3 Buyout Proposals Rejected
  April 20, 2018

• Toho Grabs 8% Stake in NKT Cell Immunotherapy Startup
  April 19, 2018

• Astellas Sells Agensys Research Facilities to Kite
  April 19, 2018

• US Appeals Court Favors Sumitomo Dainippon in Latuda Substance Patent Suit
  April 19, 2018

• FDA Clears Kyowa Kirin/Ultragenyx’s XLH Drug Burosumab
  April 19, 2018

• Tecentriq Now in PD-1/L1 NSCLC Showdown, Lynparza Also Hits Japan Market
  April 19, 2018

• PeptiStar’s Funding Procurement Nears 20 Billion Yen
  April 19, 2018

• Former GSK Japan Chief Kanako Kikuchi Named UCB Japan President
  April 19, 2018

• Pharmbio Korea Gets Rights to Shionogi’s Ospemifene
  April 18, 2018

• Another Huge Seller Re-Pricing Won’t Hit Opdivo Unless 195 Billion Yen Sales Reached: Ono Chief
  April 18, 2018

• Sumitomo Dainippon Reorganizes Drug Discovery Research System; Accelerating Decision-Making: Pres.
  April 18, 2018

• ASKA to Set Up Plant in India under JV, Eying Operation Launch in 2020
  April 18, 2018

• Novo Japan Renews Sales Record in 2017 as Tresiba, Ryzodeg Gain Ground
  April 17, 2018

• AstraZeneca Aims to Join Top League in Japan as It Plans Record 7 Launches in 2018
  April 17, 2018

• Tagrisso Selected for 23.7% of Japanese NSCLC Patients Whose Cancer Progressed on EGFR-TKIs: Observational Study
  April 17, 2018

• Eisai Teams Up with US Academia to Develop Novel TB Drugs
  April 17, 2018

• Taisho Files Taurine for Recurrence Prevention of Stroke-Like Episodes in MELAS in Japan
  April 17, 2018

• Tecentriq to Provide New Option for NSCLC: Oncologists
  April 16, 2018

• Asian Regenerative Medicine Associations Held 1st Symposium on Regulatory Harmonization in Tokyo
  April 16, 2018

• Takeda CEO Eager to Lure More Partners to Shonan iPark, Says Diversity Is Source of Creativity
  April 16, 2018

ページ

• « 先頭
• ‹ Prev
• …
• 399
• 400
• 401
• 402
• 403
• 404
• 405
• 406
• 407
• …
• Next ›
• 最終 »